logo
Liminatus Pharma, Inc. Initiates Strategic Review of Blockchain-Integrated Treasury Strategy

Liminatus Pharma, Inc. Initiates Strategic Review of Blockchain-Integrated Treasury Strategy

Business Upturn3 days ago
LA PALMA, Calif., July 22, 2025 (GLOBE NEWSWIRE) — Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies, today announced that it has initiated a strategic review to evaluate the potential inclusion of regulated digital asset strategies as part of its broader treasury management framework.
This internal review is part of Liminatus's continued commitment to strong financial stewardship and balance sheet optimization. While its core focus remains firmly on advancing cancer therapies, the Company believes it is prudent to assess innovative financial instruments—including blockchain-based assets—that may enhance treasury efficiency and diversify non-operating capital reserves.
'Liminatus remains fully committed to our mission of developing life-changing cancer therapies,' said Chris Kim, CEO of Liminatus Pharma, Inc. 'At the same time, we believe responsible treasury management is essential to supporting our long-term goals. This review is not a shift in our business focus, but an effort to evaluate modern financial tools—such as regulated digital assets—that may enhance the way we manage non-operating capital.'
Liminatus emphasizes that this is an exploratory process only. As of today, the Company has not entered into any agreements regarding the acquisition, custody, or use of digital assets. Any potential future steps would be subject to approval by the Board of Directors and undertaken in full alignment with U.S. Securities and Exchange Commission (SEC) regulations and public company disclosure standards.
About Liminatus Pharma, Inc.
Liminatus is a preclinical-stage biopharmaceutical company developing immunotherapies for patients with cancer. The Company is advancing a pipeline of novel therapies targeting cancer antigens and tumor-specific immune responses. Liminatus is also committed to responsible innovation in capital strategy to support its long-term scientific and operational objectives.
Forward-Looking Statements
Certain statements in this press release constitute forward-looking statements. Forward-looking statements include, but are not limited to, statements regarding management's expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intends,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'should,' 'will,' 'would' and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements contained in this press release are based on our current expectations and beliefs concerning future developments and their potential effects. Future developments affecting Liminatus may not be those that Liminatus has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of Liminatus), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Liminatus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws.
In addition, statements that 'we believe' and similar statements reflect beliefs and opinions on the relevant subject. These statements are based upon information available to Liminatus as of the date of this press release, and while Liminatus believes such information forms a reasonable basis for such statements, such information may be limited or incomplete, and such statements should not be read to indicate that Liminatus has conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements as predictions of future results. Liminatus's actual future results may be materially different from what it expects. Liminatus qualifies all forward-looking statements by these cautionary statements.
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Is Linde (LIN) a Safe Bet for Dividend Investors Seeking Industrial Exposure?
Is Linde (LIN) a Safe Bet for Dividend Investors Seeking Industrial Exposure?

Yahoo

time30 minutes ago

  • Yahoo

Is Linde (LIN) a Safe Bet for Dividend Investors Seeking Industrial Exposure?

Linde plc (NASDAQ:LIN) is included among the Top 10 Safest Dividend Stocks in the UK. A scientist in a lab coat inspecting a cylinder filled with industrial gas. Linde plc (NASDAQ:LIN) has created a range of technologies aimed at efficiently compressing and safely refueling hydrogen, along with solutions that help reduce the carbon footprint of hydrogen through carbon capture and storage methods. In June 2025, Linde plc (NASDAQ:LIN) entered into a long-term deal to provide industrial gases to a low-carbon ammonia plant in Louisiana. The upcoming $400 million on-site facility will enhance Linde's existing hydrogen and syngas network in the area. In the first quarter of 2025, Linde plc (NASDAQ:LIN) reported revenue of $8.1 billion, up 1% from the same period last year. The company generated $2.2 billion in operating cash flow, marking an 11% increase compared to the previous year. After accounting for $1.27 billion in capital expenditures, its free cash flow stood at $891 million. Over the course of the quarter, it returned $1.808 billion to shareholders through dividends and share buybacks, after offsetting any new stock issuances. Linde plc (NASDAQ:LIN) currently offers a quarterly dividend of $1.50 per share, having raised it by 8% in February this year. Through this increase, the company stretched its dividend growth streak to 32 years, which makes it one of the best FTSE dividend stocks. LIN offers a dividend yield of 1.27%, as of July 25. While we acknowledge the potential of LIN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Sign in to access your portfolio

AstraZeneca's (AZN) Dividend: Resilient, Predictable, and Built on Innovation
AstraZeneca's (AZN) Dividend: Resilient, Predictable, and Built on Innovation

Yahoo

time40 minutes ago

  • Yahoo

AstraZeneca's (AZN) Dividend: Resilient, Predictable, and Built on Innovation

AstraZeneca PLC (NASDAQ:AZN) is included among the Top 10 Safest Dividend Stocks in the UK. A pharmacy worker distributing prescription medicines to patientsreceiving treatment for oncology, cardiovascular, renal, metabolism and respiratory diseases. AstraZeneca PLC (NASDAQ:AZN) is well-positioned to handle upcoming patent expirations, thanks to a robust pipeline of drugs in development. By the close of the first quarter, the company had gained approval or label updates for roughly 13 treatments. Two of its most notable experimental drugs, AZD5004 and AZD6234, show potential in the weight management space. In total, the company is advancing nearly 200 research programs across its development pipeline. AstraZeneca PLC (NASDAQ:AZN) recently announced plans to invest $50 billion in the US by 2030. This initiative is expected to generate tens of thousands of direct and indirect jobs nationwide. A key part of the investment includes the development of a new multi-billion-dollar manufacturing site in the US, which will focus on producing drug substances for its weight management and metabolic treatments—such as oral GLP-1, baxdrostat, oral PCSK9, and combination small molecule therapies. This commitment comes on top of the $3.5 billion investment the company revealed in November 2024. AstraZeneca PLC (NASDAQ:AZN) is a solid dividend payer, as it has paid uninterrupted dividends to shareholders for the past 32 years. The company offers an interim dividend of $1.03 per share and has a dividend yield of 2.13%, as of July 25. While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None.

AstraZeneca's (AZN) Dividend: Resilient, Predictable, and Built on Innovation
AstraZeneca's (AZN) Dividend: Resilient, Predictable, and Built on Innovation

Yahoo

timean hour ago

  • Yahoo

AstraZeneca's (AZN) Dividend: Resilient, Predictable, and Built on Innovation

AstraZeneca PLC (NASDAQ:AZN) is included among the Top 10 Safest Dividend Stocks in the UK. A pharmacy worker distributing prescription medicines to patientsreceiving treatment for oncology, cardiovascular, renal, metabolism and respiratory diseases. AstraZeneca PLC (NASDAQ:AZN) is well-positioned to handle upcoming patent expirations, thanks to a robust pipeline of drugs in development. By the close of the first quarter, the company had gained approval or label updates for roughly 13 treatments. Two of its most notable experimental drugs, AZD5004 and AZD6234, show potential in the weight management space. In total, the company is advancing nearly 200 research programs across its development pipeline. AstraZeneca PLC (NASDAQ:AZN) recently announced plans to invest $50 billion in the US by 2030. This initiative is expected to generate tens of thousands of direct and indirect jobs nationwide. A key part of the investment includes the development of a new multi-billion-dollar manufacturing site in the US, which will focus on producing drug substances for its weight management and metabolic treatments—such as oral GLP-1, baxdrostat, oral PCSK9, and combination small molecule therapies. This commitment comes on top of the $3.5 billion investment the company revealed in November 2024. AstraZeneca PLC (NASDAQ:AZN) is a solid dividend payer, as it has paid uninterrupted dividends to shareholders for the past 32 years. The company offers an interim dividend of $1.03 per share and has a dividend yield of 2.13%, as of July 25. While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store